Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAUR | Q03405 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | PAICS | P22234 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 4/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239552 | 1.00 | PLAUR (0.47) | PLAURPIM1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL4503250 | 0.91 | PLAUR (0.55) | PLAURPIM1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL5804770 | 0.88 | LCK (0.47) | PLAURSRCGABRA1HTR2CHTR2B | |
| SCHEMBL27959668 | 0.88 | LCK (0.47) | PLAURSRCGABRA1HTR2CHTR2B | |
| SCHEMBL27956447 | 0.85 | PAICS (0.41) | PLAURPIM1EGFRSRCPAICS | |
| SCHEMBL27956450 | 0.85 | PAICS (0.41) | PLAURPIM1EGFRSRCPAICS | |
| SCHEMBL27934510 | 0.81 | BTK (0.44) | KMT2AEGFRSRCHTR2CHTR2B | |
| SCHEMBL18173591 | 0.81 | BTK (0.44) | KMT2AEGFRSRCHTR2CHTR2B | |
| SCHEMBL7047879 | 0.79 | SCN4A (0.47) | PLAURPIM1CHRNB2CHRNA4SRC | |
| Tert-Butyl Formate SCHEMBL27812253 | 0.78 | PLAUR (0.46) | PLAURPIM1KMT2ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | PLAUR 838/4885PIM1 266/4885KMT2A 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.